U.S. patent number 3,797,494 [Application Number 05/169,976] was granted by the patent office on 1974-03-19 for bandage for the administration of drug by controlled metering through microporous materials.
This patent grant is currently assigned to Alza Corporation. Invention is credited to Alejandro Zaffaroni.
United States Patent |
3,797,494 |
Zaffaroni |
* March 19, 1974 |
BANDAGE FOR THE ADMINISTRATION OF DRUG BY CONTROLLED METERING
THROUGH MICROPOROUS MATERIALS
Abstract
A bandage for use in the continuous administration of drugs to
the skin or mucosa, comprising a backing member defining one
exterior surface, a surface of pressure-sensitive adhesive defining
a second exterior surface, and disposed therebetween a reservoir
containing drug formulation confined therein. The reservoir can
comprise a distinct layer of the bandage or a plurality of
microcapsules distributed throughout the adhesive surface, and in
either case the drug can be confined within an interior chamber of
the reservoir or distributed throughout a reservoir matrix. The
drug passes through drug release rate controlling microporous
material which continuously meters the flow of drug by viscous or
diffusive transfer to the skin or mucosa at a controlled and
predetermined rate over a period of time.
Inventors: |
Zaffaroni; Alejandro (Atherton,
CA) |
Assignee: |
Alza Corporation (Palo Alto,
CA)
|
[*] Notice: |
The portion of the term of this patent
subsequent to August 10, 1988 has been disclaimed. |
Family
ID: |
27538369 |
Appl.
No.: |
05/169,976 |
Filed: |
August 9, 1971 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
812116 |
Apr 1, 1969 |
3598122 |
Aug 10, 1971 |
|
|
812117 |
Apr 1, 1969 |
3598123 |
Aug 10, 1971 |
|
|
150085 |
Jun 4, 1971 |
3731683 |
May 8, 1973 |
|
|
Current U.S.
Class: |
424/434; 424/448;
424/449 |
Current CPC
Class: |
A61K
9/7061 (20130101); A61L 15/58 (20130101); A61F
9/0017 (20130101); A61K 9/7092 (20130101); A61K
9/0004 (20130101); A61M 31/002 (20130101); A61K
9/7076 (20130101); A61K 9/7084 (20130101) |
Current International
Class: |
A61K
9/00 (20060101); A61K 9/70 (20060101); A61L
15/16 (20060101); A61L 15/58 (20060101); A61F
9/00 (20060101); A61M 31/00 (20060101); A61l
015/06 () |
Field of
Search: |
;128/260,268,156,155,296
;424/19,20,28 |
References Cited
[Referenced By]
U.S. Patent Documents
Primary Examiner: Truluck; Dalton L.
Assistant Examiner: McGowan; J. C.
Parent Case Text
RELATED APPLICATIONS
This application is a continuation-in-part of Ser. No. 812,116,
filed Apr. 1, 1969, and now issued on Aug. 10, 1971 as U.S. Pat.
No. 3,598,122 entitled "Bandage for Administering Drugs"; Ser. No.
812,117, filed Apr. 1, 1969, and now also issued on Aug. 10, 1971
as U.S. Pat. No. 3,598,123 entitled "Bandage"; and Ser. No.
150,085, filed June 4, 1971, and now issued on May 8, 1973 as U.S.
Pat. No. 3,731,683 entitled "Bandage for the Controlled Metering of
Topical Drugs to the Skin"; all being applications of Alejandro
Zaffaroni.
Claims
What is claimed is:
1. A medical bandage for the continuous administration of
controlled quantities of drug to the skin or mucosa, comprised of a
laminate of: (1) a backing member; bearing (2) a discrete middle
reservoir layer containing a drug confined within a body, the body
being comprised of drug release rate controlling microporous
material permeable to the passage of drug, to continuously meter
the flow of a therapeutically effective amount of the drug to the
skin or mucosa from the reservoir at a controlled and predetermined
rate over a period of time; and (3) a pressure-sensitive adhesive
surface adapted for contact with the skin or mucosa and postitioned
on one surface of the reservoir remote from the backing member.
2. The bandage as defined by claim 1 wherein the pores of the
microporous rate controlling material are filled with a medium to
permit controlled diffusion of the drug from the reservoir.
3. A medical bandage for the continuous administration of
controlled quantities of drug to the skin or mucosa, comprised of a
laminate of: (1) a backing member; bearing (2) a discrete middle
reservoir containing a drug confined therein, the reservoir being
formed of material permeable to passage of the drug; and (3) a
pressure-sensitive adhesive surface adapted for contact with the
skin or mucosa and positioned on one surface of the reservoir
remote from the backing member and wherein one or more drug release
rate controlling microporous membranes are interposed between the
surface of the reservoir and pressure-sensitive adhesive so as to
continuously meter the flow of a therapeutically effective amount
of the drug from the reservoir at a controlled and predetermined
rate over a period of time.
4. The bandage as defined by claim 3 wherein the reservoir is a
container having the drug confined therein.
5. The bandage as defined by claim 4 wherein the reservoir is
pressurized to permit controlled microporous flow of the drug from
the reservoir.
6. The bandage as defined by claim 3 wherein the reservoir is a
solid or microporous matrix having the drug dispersed therein.
7. The bandage as defined by claim 3 wherein the pores of the
microporous rate controlling material are filled with a medium to
permit controlled diffusion of the drug from the reservoir.
Description
BRACKGROUND OF THE INVENTION
This invention relates to a device for the administration of drug
and, more particularly, to a medical bandage for the controlled
continuous metering of flow of systemically or topically active
drug to the skin or mucosa over a period of time.
"Topically active" drugs, as that term is used in this
specification and the appended claims, are agents which, when
applied to the skin or mucosa, primarily cause a pharmacological or
physiological response at or near the site of their application.
"Systemically active" drugs, as that term is used in this
specification and the appended claims, are agents which, when
applied to the skin or mucosa, are absorbed through the body
surface to which applied and are transported from their site of
application by the recipient's circulatory system or lymphatic
system, to cause a pharmacologic or physiologic response at a
remote site in the body.
Systemically active drugs are conventionally administered either
orally or by injection, with the primary objective of the mode
being to achieve a given desired blood level of drug in circulation
over a period of time. However, these prior art methods possess
certain shortcomings resulting in the failure to obtain these
goals. For example, the oral route is inadequate for several
reasons even though the drug is administered at periodic intervals
according to a well defined schedule. The rate of absorption of
drug through the gastrointestinal tract is affected by both the
contents of the tract and the time of passage of drug through the
small intestine. Therefore, such variables as whether the drug is
administered before or after eating and the type and quantity of
food eaten (for example, high or low fat content), or whether
administered before or after a bowel movement, affect the rate of
absorption of the drug which takes place in the small intestine.
Additionally, the time of passage of drug through the small
intestine is affected by the rate of peristaltic contracting,
adding further uncertainty. Also important is the rate of
circulation of blood to the small intestine and the fact that many
drugs administered by this route are rendered inactive by gastric
acid and digestive enzymes of the gastrointestinal tract or liver
where the drug can be metabolized to an inactive product by that
organ. These factors make it difficult to achieve a desired time
course of concentration of the drug in the blood. The almost
inevitable result of oral administration of drugs through the
gastrointestinal tract is that the level of drug in circulation
surges to a peak level at the time the drug is administered,
followed by a decline in concentration in the blood and body
compartments. Thus, a plot of drug in circulation after
administration of several tablets a day has the appearance of a
series of peaks which may surpass the toxic threshold of the drug,
and valleys which fall below the critical point needed to achieve
the desired therapeutic effect.
The administration of drugs by injection can entail certain
disadvantages. For example, very strict asepsis must be maintained
to avoid infection of the blood, the vascular system or heart. Drug
administration by poor intravenous injection technique may result
in perivascular injection when it is not intended; and the typical
result of injection into the blood is a sudden rise in the blood
concentration followed by an uncontrolled decline. Additionally,
administration of drugs by injection is inconvenient and painful.
Other dosage forms for systemic administration of drug, such as
rectal suppositories and sublingual lozenges, also produce
non-uniform levels of the therapeutic agent in circulation. These
dosage forms require great patient cooperation, have low patient
acceptability, and are sparingly used throughout most of the
world.
A large number of locally acting drugs are available to treat skin
disorders or other conditions which manifest themselves in a manner
such that they are susceptible to treatment via the skin. These
drugs are conventionally topically administered to the skin with
the active agent carried in the form of ointments, creams, salves,
liniments, powders, dressings, and the like. The popularity of
these types of formulations resides in the fact that it is quite
easy to topically apply the agent to the skin in this manner. In
most cases, however, it is not possible to determine how much of
the preparation has been taken up or effectively administered to
the sking since only non-uniform levels of the agent are available,
nor is there any assurance that sufficient medication will be
available for the duration of periods that it is required. A
further undesirable feature is the unsightliness of these
formulations which often discourages patients from using them
during their waking hours of the day when they are most likely to
be seen by others. Further, the preparations are subject to rub off
onto clothing, thus causing much inconvenience and annoyance to the
user.
SUMMARY OF THE INVENTION
Accordingly, an object of this invention is to provide a bandage
for the improved continuous administration of a predetermined
controlled quantity of topically or systemically active drug to or
through the skin or body mucosa over a period of time, which
overcomes the disadvantages inherent in the aforesaid prior art
modes of administration.
Another object of this invention is to provide a bandage which can
be adapted to deliver controlled quantities of drug having a wide
variety of chemical and physical properties and over a wide range
of drug delivery rates.
In accomplishing these objects, one feature of the invention
resides in a bandage for the continuous administration of
controlled quantities of drug to the skin or mucosa, comprised of a
laminate of: (1) a backing member; bearing (2) a discrete middle
reservoir layer containing a drug confined within a body, the body
being formed from drug release rate controlling microporous
material permeable to the passage of the drug, to continuously
meter the flow of a therapeutically effective amount of the drug to
the skin or mucosa from the reservoir at a controlled and
predetermined rate over a period of time; and (3) a
pressure-sensitive adhesive surface adapted for contact with the
skin or mucosa and positioned on one surface of the reservoir
remote from the backing member.
Another aspect of this invention resides in a bandage comprised of
a laminate of: (1) a backing member; bearing (2) a discrete middle
reservoir containing a drug confined therein, the reservoir being
formed of material permeable to passage of the drug; and (3) a
pressure-sensitive adhesive surface adapted for contact with the
skin or mucosa and positioned on one surface of the reservoir
remote from the backing member and wherein one or more drug release
rate controlling microporous membranes are interposed between the
surface of the reservoir and pressure-sensitive adhesive so as to
continuously meter the flow of a therapeutically effective amount
of the drug from the reservoir at a controlled and predetermined
rate over a period of time. The reservoir can be a container having
the agent confined therein or a solid or microporous matrix having
agent dispersed therein.
Still another embodiment of this invention resides in an adhesive
bandage comprising a laminate of: (1) a backing member; bearing (2)
a pressure-sensitive adhesive on one surface thereof adapted for
contact with the skin or mucosa, said pressure-sensitive adhesive
having distributed therethrough, (3) a plurality of discrete
microcapsules, each of which microcapsules comprises a drug
confined within a body of drug release rate controlling porous
material to continuously meter the flow of a therapeutically
effective amount of the drug to the skin or mucosa of the patient
from the microcapsules at a controlled and predetermined rate over
a period of time.
Other objects, features and advantages of the invention will become
more apparent from the following description when taken in
conjunction with the accompanying drawings.
The term "reservoir", as used herein to define the drug containing
portion of the subject bandage, is intended to connote a broad
class of structures capable of fulfilling the intended function,
and includes both discrete porous microcapsules, as well as
distinct reservoir compartments or layers. Likewise, as will be
hereinafter more completely developed, the foregoing term
encompasses containers having one or more interior drug containing
chambers, as well as solid matrices and microporous matrices having
a systemically or topically active drug distributed
therethrough.
The term "drug or agent", when not further qualified, includes both
topically active and systemically active drugs, as hereinbefore
defined.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings:
FIG. 1 is a cross-sectional view of an embodiment of the medical
bandage of the invention, wherein the drug is uniformly distributed
throughout a matrix of microporous material permeable to the
passage of the drug by flow through the pores of the material and
the material is laminated to a backing member. The matrix material
which acts as a reservoir for the drug bears a coating of the
pressure-sensitive adhesive thereon;
FIG. 2 is a cross-sectional view of still another embodiment of the
invention, wherein the adhesive bandage of the invention is
comprised of a backing member having a reservoir on one surface
thereof of drug uniformly distributed throughout a matrix material
permeable to passage of the drug, and on the surface of the
reservoir remote from the backing member bearing a
pressure-sensitive adhesive coating. A microporous membrane is
interposed between the reservoir layer and the pressure-sensitive
adhesive coating;
FIG. 3 is a cross-sectional view of another embodiment of the
bandage of the invention, wherein the reservoir laminated to the
backing member is a hollow container permeable to passage of drug
by flow through the pores of one surface thereof, and having the
drug confined within the interior chamber thereof. The reservoir
bears a coating of pressure-sensitive adhesive thereon;
FIG. 4 is a perspective view of the medical adhesive bandage of the
invention, wherein the drug is microencapsulated with a porous
material permeable to the passage of the drug, and the
microcapsules are uniformly distributed throughout the
pressure-sensitive coating;
FIG. 5 is a cross-sectional view of the bandage of the invention
shown in FIG. 4.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with this invention there is provided a bandage
suitable, by virtue of the microporous materials employed therein,
for the predetermined controlled administration of drug to the skin
or mucosa of the body over a period of time. To use the bandage of
the invention it is applied to the patient's skin or mucosa and
should be in firm contact therewith so as to form a tight seal.
Flow of drug from the reservoir is metered through the pores of the
rate release controlling material in accordance with the laws of
hydrodynamics or diffusion, as hereinafter discussed, at a
predetermined rate. In operation, drug molecules are continuously
removed from the reservoir and migrate to the skin or mucosa of the
patient. In the case of systemic drugs, the drugs are absorbed by
the skin or mucosa and enter circulation through the capillary
network.
The reservoir containing the drug is formed of material permeable
to the drug to permit passage of the drug. Depending upon the
particular embodiment as described above, the drug reservoir can be
of microporous material or otherwise. However, as is apparent in
the latter case, the drug must first pass through a microporous
membrane material prior to reaching the skin or mucosa. It is
therefore critical to the practice of this invention for all
embodiments that, at some point after or concurrent with the
release of drug from the reservoir and prior to reaching the skin
or mucosa, the drug pass through the drug release rate controlling
microporous membrane or matrix material to meter the flow thereof.
The rate of passage or permeation of drug through the microporous
material is determined by the transfer mechanism which can be
either by:
1. diffusive flux of drug molecules as is the case, as hereinafter
described, where the micropores of the rate controlling microporous
membrane or matrix material are impregnated with a diffusive medium
for the drug in which the drug molecules can dissolve in and flow
through to a direction of lower chemical potential; or
2. pressure induced viscous type flow of drug molecules through the
pores in the microporous membrane or matrix rate controlling
material.
Thus, the microporous material has a structure that enables the
drug to pass through the pre-existing pores or capillaries, either
by diffusive permeability or microporous hydrodynamic flow,
depending upon the mode of use as describd hereinafter. Since the
microporous rate controlling material is preferably selected so
that the drug is substantially insoluble therein, as hereinafter
described, flow of drug through the structure of the material can
be neglected.
For drug transfer mechanism (1) set forth above, i.e., wherein the
drug diffuses through a diffusive medium for the drug, the release
rate can be controlled in accordance with Fick's First Law,
depending on the particular design by selection of dependent
variables such as the diffusivity and solubility of the drug in the
diffusive medium and the thickness and porosity of the material
properly modified by a tortuosity factor. For drug transfer
mechanism (2), i.e., flow of drug through the pores of the
microporous rate controlling material, the pressure differential,
the thickness of the membrane, the viscosity of the permeant drug,
the size of the permeant molecule relative to the pore size, the
absolute value of the pore size, and the number of pores or percent
voids in the material are the controlling factors governing
permeability. For the simplest type of flow mechanism of this type,
e.g., viscous flow, the amount of drug passing through the porous
structure is given by Poiseuille's equation for viscous flow.
Therefore, the selection of appropriate materials for fabricating
the microporous rate controlling membrane or matrix material will
be dependent on the particular drug to be used in the bandage. Both
organic and inorganic polymeric materials can be shaped into a wide
variety of forms with tailored morphology and a wide range of
chemical and physical properties to advantageously control release
of a wide variety of drugs, including those with large molecular
structures such as insulin, and over a large dosage range rate
appropriate pore size selection. Additionally, by impregnating the
interconnected pores of the microporous structure with a diffusive
medium for the drug to be administered, a given microporous
membrane or matrix material can be adapted to control the release
of drugs having a wide range of chemical properties by diffusive
permeability. Thus, by varying the composition, pore size, and
effective thickness of the microporous rate controlling material,
the viscosity of the drug to be administered by appropriate
formulation or by impregnating the material with suitable solvent,
the dosage rate per area of bandage can be controlled since the
material functions to meter the flow of drug from the device.
Therefore, bandages of the same surface area can provide different
dosages of a drug by varying the above discussed parameters.
The microporous rate controlling materials of this invention are
known in the art and can be visualized as a plurality of
sponge-like fused polymer particles which provide a supporting
structure having therethrough a dispersion of microscopic sized
interconnecting voids or pores. The rate controlling structures
formed from the materials can be isotropic, wherein the structure
is homogeneous throughout the cross-section of the matrix or
membrane material, or anisotropic wherein the structure is
non-homogenous. These rate controlling structures are commercially
available and can be made by a multitude of different methods,
e.g., etched nuclear track, and materials employed, e.g.,
polyelectrolyte, ion exchange polymers, as described in R. E.
Kesting, Synthetic Polymer Membranes, McGraw Hill, Chapters 4 and
5, 1971; J. D. Ferry, Ultrafiltration Membranes, Chemical Review,
Vol. 18, Page 373, 1934. Materials possessing from 5 percent to 95
percent voids and having an effective pore size of from about 10
angstroms to about 100 microns can be suitably employed in the
practice of this invention. Materials with pore sizes significantly
below 50 angstroms can be considered to be molecular diffusion type
membranes and matrices. In order to obtain the most advantageous
results, the materials should be formed into structures with the
desired morphology in accordance with methods known to those
skilled in the art to achieve the desired release rate of drug.
Additionally, the material must have the appropriate chemical
resistance to the drug used and be non-toxic when used as an
element of the bandage of the invention.
Materials useful in forming the microporous rate controlling
materials used in this invention include, but are not limited to
the following.
Polycarbonates, i.e., linear polyesters of carbonic acids in which
carbonate groups recur in the polymer chain, by phosgenation of a
dihydroxy aromatic such as bisphenol A. Such materials are sold
under the trade designation Lexan by the General Electric
Company.
Polyvinylchlorides; one such material is sold under the trade
designation Geon 121 by B. G. Goodrich Chemical Company.
Polyamides such as polyhexamethylene adipamide and other such
polyamides popularly known as "nylon". One particularly
advantageous material is that sold under the trade name "NOMEX" by
E. I. DuPont de Nemours & Co.
Modacrylic copolymers, such as that sold under the trade
designation DYNEL and formed of polyvinylchloride (60 percent) and
acrylonitrile (40 percent), styrene-acrylic acid copolymers, and
the like.
Polysulfones such as those of the type characterized by diphenylene
sulfone groups in the linear chain thereof are useful. Such
materials are available from Union Carbide Corporation under the
trade designation P-1700.
Halogenated polymers such as polyvinylidene fluoride sold under the
trade designation Kynar by Pennsalt Chemical Corporation,
polyvinylfluoride sold under the trade name Tedlar by E. I. DuPont
de Nemours & Co., and the polyfluorohalocarbon sold under the
trade name Aclar by Allied Chemical Corporation.
Polychloroethers such as that sold under the trade name Penton by
Hercules Incorporated, and other such thermoplastic polyethers.
Acetal polymers such as the polyformaldehyde sold under the trade
nambe Delrin by E. I. DuPont de Nemours & Co., and the
like.
Acrylic resins such as polyacrylonitrile polymethyl methacrylate,
poly n-butyl methacrylate and the like.
Other polymers such as polyurethanes, polyimides,
polybenzimidazoles, polyvinyl acetate, aromatic and aliphatic,
polyethers, cellulose esters, e.g., cellulose triacetate;
cellulose; collodion (cellulose nitrate with 11% nitrogen); epoxy
resins; olefins, e.g., polyethylene polypropylene; porous rubber;
cross-linked poly (ethylene oxide); cross-linked
polyvinylpyrrolidone; cross-linked poly (vinyl alcohol);
polyelectrolyte structures formed of two ionically associated
polymers of the type as set forth in U.S. Pat. Nos. 3,549,016 and
3,546,142; derivatives of polystyrene such as poly (sodium
styrenesulfonate) and polyvinylbenzyltrimethyl-ammonium chloride);
poly(hydroxyethyl methacrylate); poly(isobutyl vinyl ether), and
the like, may also be utilized. A large number of copolymers which
can be formed by reacting various proportions of monomers from the
aforesaid list of polymers are also useful for preparing rate
controlling structures useful in the invention.
As illustrated in FIG. 1, the bandage 20 of the invention is
comprised of drug 24 uniformly distributed in the interstices of
the microporous matrix material forming reservoir 22. The matrix
material is laminated to backing member 21 and bears a
pressure-sensitive adhesive coating 23 thereon. The microporous
matrix material 22 functions to control the release rate of the
drug impregnated therein. The reservoir can be prepared by
employing any of the known impregnating techniques. Thus, the drug
can be added to the rate controlling material in liquid form and
uniformly distributed therethrough by mixing, and subsequently
converted to a microporous structure by the various methods known
to the art. One such method calls for dissolving a natural or
synthetic polymer in a suitable solvent in which it has sufficient
solubility to permit the preparation of a solution that is
sufficiently viscous for conventional film casting. The preferred
method is to cast a film of a polymer solution having the drug
therein, and, shortly after casting, to immerse it in a non-solvent
or "diluent," a medium which is compatible with the solvent, but
not a solvent for the polymer. The original solution then forms two
phases, one polymer-rich and one polymer-poor. Under the proper
conditions, both of these phases are physically continuous, so that
the resulting polymer membrane is mechanically reasonably strong,
but it is completely interlaced with continuous pores. The size and
uniformity of the pores depend on the conditions of preparation.
Alternatively, preformed microporous materials can be impregnated
with drug by immersion in a bath of the drug to diffuse the drug
into the material. While the matrix material can be of any
convenient thickness, typically a thickness of from 20 to 200
microns is employed.
FIG. 2 illustrates a further modified form of the invention wherein
the adhesive bandage 30 of the invention is comprised of a backing
member 21 having a reservoir 32 on one surface thereof. A
microporous rate controlling membrane 35 is interposed between the
reservoir 32 and a pressure-sensitive adhesive coating 23. Drug 24
is confined in polymeric matrix material 32 which acts as the
reservoir for the drug. Matrix material 32 can be solid material as
illustrated, or microporous as illustrated for reservoir 22 in FIG.
1. If desired, additional membranes can be juxtaposed next to
membrane 35 in order to achieve optimum rate release properties.
The matrix material 32 when solid or microporous should have a
release rate to drug which is higher than that of the rate
controlling microporous membrane 35, such that passage through the
latter is the rate controlling step. Materials used to form the
matrix reservoir 32 of FIG. 2, when solid, can be those heretofore
exemplified for preparing the microporous rate controlling material
and, in addition, include hydrophobic polymers such as plasticized
or unplasticized polyvinylchloride, plasticized nylon, plasticized
soft nylon, plasticized polyethyleneterephthalate, natural rubber,
C.sub.2 --C.sub.4 olefins, e.g., polyethylene, polyisoprene,
polyisobutylene, polybutadiene; silicone rubbers, especially the
medical grade polydimethylsiloxanes, as described in U.S. Pat. No.
3,279,996, hydrophilic polymers such as the hydrophilic hydrogels
of esters of acrylic and methacrylic acid (as described in U.S.
Pat. Nos. 2,967,576 and 3,220,960, and Belgian Patent No. 701,813),
modified collagen, cross-linked polyvinylalcohol, and cross-linked
partially hydrolyzed polyvinylacetate. Of course, these materials
used to form the matrix must be permeable to passage of the drug,
as by diffusion. Accordingly, selection of appropriate materials
will, in each instance, be dependent on the particular drug to be
administered.
FIG. 3 illustrates a further form of the invention wherein bandage
40 includes a backing member 21 and a reservoir 42 in the form of a
hollow container having an interior chamber 43 containing drug 34.
Wall or surface 45 of reservoir 42, remote from backing member 21,
is of a microporous membrane structure permeable to passage of drug
34, to meter the flow of drug to pressure-sensitive adhesive layer
23 on the outer surface thereof. The sides of the reservoir 42,
other than rate controlling microporous membrane 45, preferably are
impermeable to passage of the drug, and can be made of the same
materials used to make the backing member as hereinafter described.
As discussed, one face surface of the drug reservoir bears a
backing member 21. The purpose of the backing is to prevent passage
of the drug through the surface of the reservoir distant from the
adhesive layer. An ancillary purpose of the backing is to provide
support for the bandage where needed. When the outer surface of the
reservoir 33 is impermeable to the drug and strong enough, the
backing becomes unnecessary. The other surface of the reservoir
bears a coating of a pressure-sensitive adhesive.
If desired, additional microporous rate controlling membranes can
be juxtaposed on top of membrane 45 to further tailor the rate of
flow of drug. Of course, in each instance, the membrane will have
different characteristics than the reservoir membrane 45 of the
particular device. This use of a pair of multiplicity of membranes,
that is, the reservoir wall and the further membrane, allows for
precise metering of drug out of the reservoir; for the thickness,
porosity and composition of both membranes can be varied to provide
for wide range of dosage levels for a given area of bandage. It
will be appreciated that this type of membrane can be used with
either the matrix (FIGS. 1 or 2) or container type (FIG. 3) of
reservoir. To provide additional mechanical strength, if necessary,
the rate controlling microporous membrane 45 can be supported by an
appropriate mesh or screen having a greater release rate to drug
than does membrane 45.
The reservoir of the embodiment in FIG. 3 can be formed by molding
into the form of a hollow container with the drug trapped therein.
While the non-rate controlling walls of the reservoir can be of any
convenient thickness, usually they have a thickness of from 0.01 to
7 millimeters. The rate controlling membranes 35 and 45, in FIGS. 2
and 3, respectively, can have varying thickness depending upon the
nature of the membrane, its porosity and the number of membranes
used in combination. Typically, a thickness of from 20 to 200
microns is employed.
It will, of course, be appreciated that the pressure-sensitive
adhesive surface need not form a continuous layer on the subject
bandage. Particularly in the case of a bandage having a distinct
reservoir layer, equally advantageous results are obtained by
providing an annular surface of adhesive around the periphery of
the bandage face. In this manner a liquid tight adhesive seal
between the bandage and the patient's skin or mucosa is maintained,
and at the same time, drug may be directly absorbed by the skin
from the exposed surface of the drug reservoir layer without first
migrating through an adhesive layer. As a further alternative, in
the embodiment of the invention employing a distinct reservoir
layer, to prevent passage of the drug into the adhesive layer prior
to use, the adhesive can be supplied separately from the reservoir
and backing, with the device assembled at the point of use. For
example, the adhesive in sheet form can have both surfaces
protected with a release film and the wall of the reservoir can be
similarly protected. At the point of use, the release films can be
removed from the reservoir and one surface of the adhesive, the
adhesive sheet applied to the reservoir wall to complete assemblage
of the bandage, the remaining release film then removed from the
adhesive, and the bandage then applied to the patient.
As previously discussed, one type of drug transfer mechanism is
that of flow through the pores or pinholes in microporous rate
controlling material. A driving force, i.e., a pressure
differential across the microporous material, is necessary to cause
the flow of drug by this mode. The bandage of the type illustrated
in FIG. 3, wherein the reservoir is a hollow container, can be
conveniently adapted to meter the flow of drug by a microporous
hydrodynamic mechanism by pressurizing the container. This can
suitably be accomplished by admixing with the drug a solid
particulate material which liberates gas on contact with the drug
formulation. For example, in the case wherein the formulation is of
an aqueous nature, a conventional effervescent powder such as a
mixture of citric acid and sodium bicarbonate can be inserted
immediately prior to use through an opening in the reservoir wall
so provide for this purpose. After insertion of the effervescent
material, the opening is sealed, for example, by means of an
adhesive tape. The pressure can be controlled by adjusting the
particle size of the effervescent powder composition and the
quantity thereof. Pressure in an amount of from 1 mm to 50 mm of
mercury can be satisfactorily employed, with the actual amount
depending upon the desired release rate and the other parameters
previously discussed regarding viscous flow.
FIGS. 4 and 5 illustrate an adhesive bandage 10 of the invention
including a backing member 11 bearing a pressure-sensitive adhesive
coating 12 on one surface thereof. Adhesive coating 12 has
uniformly distributed therethrough microcapsules 13 comprising drug
encapsulated with a microporous rate controlling material permeable
to passage of the drug. Thus, in the embodiment illustrated herein,
porous microcapsules 13 constitute the drug reservoir.
To provide the microcapsules, the encapsulating material can be
uniformly impregnated with the drug to form microcapsules which are
a porous matrix having the drug distributed therethrough.
Alternatively, particles of drug can be encapsulated with a thin
microporous coating of the encapsulating material to form
microcapsules having an interior chamber containing the drug. If
desired, particles of a matrix, such as starch, gum acacia, gum
tragacanth, and polyvinylchloride, can be impregnated with the drug
and encapsulated with other materials such as the microporous rate
controlling materials previously described, which function to meter
the flow of drug to the adhesives; use of a microporous matrix and
a different rate controlling membrane coating to slow the passage
of the drug from the microcapsules, which is desirable with drugs
that are released too rapidly from available encapsulating
materials, is therefore also contemplated herein.
Any of the encapsulation or impregnation techniques known in the
art can be used to prepare the microcapsules to be incorporated
into the pressure-sensitive adhesive in accord with the embodiment
of FIGS. 4 and 5. The porous microcapsules can be made by
techniques as set forth in U.S. Ser. No. 751,251, corresponding to
German Patent No. 1,939,066, entitled "Microcapsules with
Anisotropic Microporous Liquid Permeable Polymeric Outer Skin and
Internal Macroporous Support Partitions or Structure," Bixler,
Michaels, and Sternberg, or by standard coacervation methods. The
coacervation method of fabrication, as conventionally employed,
consists essentially of the formation of three immiscible phases, a
liquid manufacturing phase, a core material phase and a coating
phase with deposition of the liquid polymer coating on the core
material and rigidizing the coating, usually by thermal,
cross-linking or desolvation techniques to form microcapsules.
Usually, the microcapsules made by the above techniques have an
average particle size of from several tenths of a micron to 5,000
microns, although this feature is not critical to the practice of
the invention. Techniques for preparing microcapsules, such as the
classic Bungenberg de Jong and Kass method are reported in Biochem.
Z, Vol. 232, Pg. 338 to 345, 1931; Colloid Science, Vol. 11,
"Reversible System", edited by H. R. Kruyt, 1949, Elsevier
Publishing Company, Inc., New York; J. Pharm. Sci., Vol. 59, No.
10, Pg 1367 to 1376, 1970; and, Remington's Pharmaceutical Science,
Vol. XIV, Pg. 1676 to 1677, 1970, Mack Publishing Company, Easton,
Pennsylvania. Thus, the drug can be added to the encapsulating
material in liquid form and uniformly distributed therethrough by
mixing and then forming the microcapsules by any of the above set
forth methods. Alternatively, the porous microparticles can be made
by the above techniques and impregnated with drug. Still another
method is to impregnate a porous solid encapsulating material with
a drug by immersion in a bath of the drug to diffuse the drug into
the material, and subsequently the solid material can be reduced to
fine microcapsules by grinding, each of the microcapsules
comprising drug coated with and distributed throughout the
encapsulating material. Further, drug can be encapsulated with a
microporous coating by suspending dry particles of the drug in an
air stream and contacting that stream with a stream containing the
encapsulating material to coat the drug particles. Usually, the
micro-capsules have an average particle size of form 1 to 1000
microns, although this is not critical to the invention. The
microcapsules, however made, are then mixed by conventional
methods, e.g., stirring, ballmilling, and the like, with a
pressure-sensitive adhesive. The mixture of microcapsules and
pressure-sensitive adhesive is then coated onto a backing member,
usually to provide an adhesive layer 0.01 to 7 millimeters thick,
although these limits can be exceeded if more or less drug is
required. The purpose of the backing is to provide support for the
bandage and to prevent passage of the drug through the adhesive
surface away from the body surface to which the bandage is
applied.
As above discussed, the microporous rate controlling materials can
be adapted to control the release of drug by diffusive permeation
wherein the micropores are impregnated or otherwise filled with a
diffusive medium for the drug to be administered. The material can
be impregnated with the diffusive medium by methods well known to
the art, e.g., as by immersion in a bath of the material to permit
the diffusive medium material to fully saturate the micropores. The
impregnation technique can be employed with any of the embodiments
represented herein. In embodiments illustrated in FIGS. 1, 4 and 5
the micropores can be concurrently impregnated with both drug and
diffusive medium material.
In cases where the pressure-sensitive adhesive and microporous rate
controlling material employed are water permeable, body fluids will
self-migrate into the microporous material after the bandage has
been in contact with the skin for a suitable period of time to
provide the diffusive medium, as hereinafter described, without the
necessity of carrying out a separate impregnation step.
Additionally, the pores can be self-filled by migration of the
diffusive medium by contact with the composition employed to
prepare the drug formulation, as later described.
The diffusive medium is one which enables the drug to dissolve
therein and flow by diffusion at the desired rate. It can be either
of a liquid or solid nature and be a poor or good solvent for the
drug. A medium with poor solvent properties for the drug is desired
when the required release rate is low and of course the converse is
true when the desired release rate is high.
The art provides many useful approaches to enable selection of
particular solvent-drug systems. Specific attention is called to
Remington's Pharmaceutical Sciences, Chapters 19 and 71. The
solvent selected must be non-toxic and one in which the rate
controlling microporous material has the required solubility. The
materials which are useful for impregnating the micropores can be
polar, semi-polar or non-polar. Exemplary are any of the
pharmaceutically acceptable solvents such as water, alcohols
containing 2 to 10 carbon atoms, such as hexanol, cyclohexanol,
benzylalcohol, 1,2-butanediol, glycerol, and amyl alcohol;
hydrocarbons having 5 to 12 carbon atoms such as n-hexane,
cyclohexane, and ethyl benzene; aldehydes and ketones having 4 to
10 carbon atoms such as heptyl aldehyde, cyclohexanone, and
benzaldehyde; esters having 4 to 10 carbon atoms such as amyl
acetate and benzyl propionate; etheral oils such as oil of
eucalyptus, oil of rue, cumin oil, limonene, thymol, and 1-pinene;
halogenated hydrocarbons having 2 to 8 carbon atoms such as n-hexyl
chloride, n-hexyl bromide, and cyclohexyl chloride; or mixtures of
any of the foregoing materials. Also suitable are many of the
conventional non-toxic plasticizers used in the fabrication of
microporous rate controlling material, e.g., octyl diphenyl
phosphate. When these plasticizers are suitable diffusive materials
for the drug used, advantageously, the necessity for filling the
pores by a separate step is thus obviated. Other plasticizers known
to the art can be employed, such as long-chain fatty amides, higher
alcohols, and high boiling esters such as di(isooctyl) sebacate or
di(2-ethyl hexyl) phthalate.
It is preferred that the diffusive medium also be incorporated in
the reservoir in combination with the drug in the form of a
pharmaceutically acceptable carrier as hereinafter described.
In practicing this invention one can employ any systemically active
drug which will be absorbed by the body surface to which the
bandage is applied, consistent with their known dosages and uses.
Of course, the amount of drug necessary to obtain the desired
therapeutic effect will vary depending on the particular drug used.
Suitable systemic drugs include, without limitation, Anti-microbial
Agents such as penicillin, tetracycline, oxytetracycline,
chlortetracycline, chloramphenicol, and sulfonamides; Sedatives and
Hypnotics such as pentabarbital sodium, phenobarbital, secobarbital
sodium, codeine, (.alpha.-bromoisovaleryl) urea, carbromal, and
sodium pheno-barbital; Psychic Energizers such as 3-(2-aminopropyl)
indole acetate and 3-(2-aminobutyl) indole acetate; Tranquilizers
such as reserpine, chlorpromazine hydrochloride, and thiopropazate
hydrochloride; Hormones such as adrenocorticosteroids, for example,
6.alpha.-methylprednisolone; androgenic steroids, for example,
methyltestosterone, and fluoxymesterone; estrogenic steroids, for
example, estrone, 17.beta.-estradiol and ethinyl estradiol;
progestational steroids, for example, 17.alpha.-hydroxyprogesterone
acetate, medroxyprogesterone acetate, 19-norprogesterone, and
norethindrone; and thyroxine; Antipyretics such as aspirin,
salicylamide, and sodium salicylate; morphine and other narcotic
analgesics; Antidiabetics, e.g., insulin; Cardiovascular Agents,
e.g., nitroglycerin, and cardiac glycosides such as digitoxin,
digoxin, ouabain; Anti-spasmodics such as atropine, methscopolamine
bromide, methscopolamine bromide with phenobarbital; Anti-malarials
such as the 4-aminoquinolines, 9-amino-quinolines, and
pyrimethamine; and Nutritional Agents such as vitamins, essential
amino acids, and essential fats.
Additionally, in practicing this invention one can employ a wide
variety of topically active drugs consistent with their known
dosages and uses. Suitable drugs include, without limitation:
Antiperspirants, e.g., aluminum chloride; Deodorants, e.g.,
hexachlorophene, methylbenzethonium chloride; Astringents, e.g.,
tannic acid; Irritants, e.g., methyl salicylate, camphor,
cantharidin; Keratolytics, e.g., benzoic acid, salicylic acid,
resorcinol, iodochlorhydroxyquin; Antifungal Agents, such as
tolnaftate, griseofulvin, nystatin and amphotericin;
Anti-inflammatory Agents, such as corticosteroids, e.g.,
hydrocortisone, hydrocortisone acetate, prednisolone,
methylprednisolone, triamcinolone acetonide, fludrocortisone,
flurandrenolone, flumethasone, dexamethasone sodium phosphate,
bethamethasone valerate, fluocinolone acetonide; fluorometholone;
and pramoxine HC1; Anti-neoplastic Agents, e.g., methotrexate; and
Antibacterial Agents, such as bacitracin, neomycin, erythromycin,
tetracycline HC1, chlortetracycline HC1, chloramphenicol,
oxytetracycline, polymyxin B, nitrofuraxone, mafenide
(.alpha.-amino-p-toluenesulfonamide), hexachlorophene, benzalkonium
chloride, cetalkonium chloride, methylbenzethonium chloride, and
neomycin sulfate.
It will be appreciated, with regard to the aforesaid list of drugs,
that characterization of the drug as either "systemically or
topically" active is done for purposes of convenience only.
Further, a given drug can be both systemically and topically active
depending upon its manner of use.
In addition to the aforementioned drugs, simple pharmacologically
acceptable derivatives of the drugs, such as ethers, esters,
amides, acetals, salts, etc., or formulations of these drugs,
having the desired polymeric permeability or transport properties
can be prepared and used in practicing the invention. Drugs
mentioned above can be used alone or in combination with others and
each other. Of course, the derivatives should be such as to convert
to the active drugs within the body through the action of body
enzyme assisted transformations, pH, etc.
The above drugs and other drugs can be present in the reservoir
alone or in combination form with pharmaceutical carriers. The
pharmaceutical carriers acceptable for the purpose of this
invention are the art known carriers that do not adversely affect
the drug, the host, or the material comprising the drug delivery
device. Suitable pharmaceutical carriers include sterile water;
saline, dextrose; dextrose in water or saline; condensation
products of castor oil and ethylene oxide combining about 30 to
about 35 moles of ethylene oxide per mole of castor oil; liquid
glyceryl triester of a lower molecular weight fatty acid; lower
alkanols; oils such as corn oil; peanut oil, sesame oil and the
like, with emulsifiers such as mono-or di-glyceride of a fatty
acid, or a phosphatide, e.g., lecithin, and the like; glycols;
polyalkylene glycols; aqueous media in the presence of a suspending
agent, for example, sodium carboxymethylcellulose; sodium alginate;
poly(vinylpyrrolidone); and the like, alone, or with suitable
dispensing agents such as lecithin; polyoxyethylene stearate; and
the like. The carrier may also contain adjuvants such as
preserving, stabilizing, wetting, emulsifying agents, and the
like.
The drug can also be mixed in the reservoir with a transporting
agent, that is, a material that aids or assists the drug delivery
device to achieve the administration of a drug to a drug receptor,
for example, by enhancing penetration through the skin. The
transporting aids suitable for the purpose of the invention are the
therapeutically acceptable transporting aids that do not adversely
affect the host, the drug, or alter or adversely affect the
materials forming the drug delivery device. The transporting aids
can be used alone or they can be admixed with acceptable carriers
and the like. Exemplary of transporting aids include manovalent,
saturated and unsaturated aliphatic cycloaliphatic and aromatic
alcohols having 4 to 12 carbon atoms, such as hexanol, cyclohexane
and the like; aliphatic cycloaliphatic and aromatic hydrocarbons
having from 5 to 12 carbon atoms such as hexane, cyclohexane,
isopropylbenzene and the like; cycloaliphatic and aromatic
aldehydes and ketones having from 4 to 10 carbon atoms such as
cyclohexanone; acetamide; N,N-di(lower) alkyl acetamides such as
N,N-diethyl acetamide, N,N-dimethyl acetamide, N-(2-hydroxyethyl)
acetamide, and the like; and other transporting agents such as
aliphatic, cycloaliphatic and aromatic esters; N,N-di-lower alkyl
sulfoxides; essential oils; halogenated or nitrated aliphatic,
cycloaliphatic and aromatic hydrocarbons; salicylates; polyalkylene
glycol silicates; mixtures thereof; and the like.
The amount of active agent to be incorporated in the bandage to
obtain the desired therapeutic effect will vary depending upon the
desired dosage, the permeability of the rate controlling materials
of the bandage which are employed to the particular agent to be
used, and the length of time the bandage is to remain on the skin
or body mucosa. Since the bandage of this invention is designed to
control drug administration for an extended period of time, such as
1 day or more, there is no critical upper limit on the amount of
agent incorporated into the bandage. The lower limit is determined
by the fact that sufficient amounts of the agent must remain in the
bandage to maintain the desired dosage. In order to achieve a
therapeutic effect in a human adult, the daily release dosage of
atropine should be in the range of between 200 and 600 micrograms
per day. Thus, for example, using atropine and with a bandage
intended to remain in place for 1 week, and with a release rate of
500 micrograms of atropine per day, at least 3.5 mg of atropine
would be incorporated in the bandage. Generally, the drug delivery
bandages made according to the invention can release at a
controlled rate about 25 nanograms to about 1 gram of drug or
larger amounts per day. Of course, other devices for use for
different time periods such as week or month are also readily made
by the invention.
The effective rate of release of the active agent to the skin or
mucosa can be in the range of from 0.5 to 1000 micrograms per
square centimeter of bandage per day. The exact amount will depend
on the desired dosage as well as the condition to be treated. The
desired effective rate of release of active agent can be obtained
by altering the earlier discussed parameters affecting the release
rate controlling barrier. In the case of the micro-encapsulated
active agent, the release rate can also be controlled by varying
the number of microcapsules present in a given volume of the matrix
of the device. This is a particularly desirable feature of this
aspect of the invention. Additionally, the duration of action of
the device can be altered by controlling the amount of active agent
initially incorporated consistent with the release rate. Further,
the release rate of drug, as well as the duration of release of the
drug from the device, can be predetermined to be in consonance with
the optimum therapeutic values. Once this dosage level in
micrograms per square centimeter of bandage has been determined,
the total amount of drug to be incorporated in the bandage can be
established by obtaining the release rate of the agent in the
particular material or materials which are to be used. Those
skilled in the art can readily determine the rate of permeation of
agent through the porous rate controlling material or selected
combinations of rate controlling materials. Standard techniques are
described in Encyl. Polymer Science and Technology, Vo. 5 and 9,
Pg. 65 to 85 and 795 to 807, 1968; and the references cited
therein.
Any of the well-known dermatologically acceptable
pressure-sensitive adhesives can be used in practicing this
invention. Exemplary adhesives include acrylic or methacrylic
resins such as polymers of esters of acrylic or methacrylic acid
with alcohols such as n-butanol, n-pentanol, isopentanol, 2-methyl
butanol, 1-methyl butanol, 1-methyl pentanol, 2-methyl pentanol,
3-methyl pentanol, 2-ethyl butanol, isooctanol, n-decanol, or
n-dodecanol, alone or copolymerized with ethylenically unsaturated
monomers such as acrylic acid, methacrylic acid, acrylamide,
methacrylamide, N-alkoxymethyl acrylamides, N-alkoxymethyl
methacrylamides, N-tert. butylacrylamide, itaconic acid,
vinylacetate, N-branched alkyl maleamic acids wherein the alkyl
group has 10 to 24 carbon atoms, glycol diacrylates, or mixtures of
these; natural or synthetic rubbers such as silicone rubber,
styrenebutadiene, butyl-ether, neoprene, polyisobutylene,
polybutadiene, and polyisoprene; polyurethane elastomers; vinyl
polymers, such as polyvinylalcohol, polyvinyl ethers, polyvinyl
pyrrolidone, and polyvinylacetate; ureaformaldehyde resins;
phenolformaldehyde resins; resorcinol formaldehyde resins,
cellulose derivatives such as ethyl cellulose, methyl cellulose,
nitrocellulose, cellulose acetate-butyrate, and carboxymethyl
cellulose; and natural gums such as guar, acacia, pectins, starch,
dextrin, albumin, gelatin, casein, etc. The adhesives may be
compounded with tackifiers and stabilizers as is well know in the
art.
When the adhesive layer covers one face surface of the bandage or
when the reservoir is in the form of microcapsules distributed
throughout the adhesive, the adhesive must be permeable to passage
of the drug to allow drug released from the reservoir to reach the
outer surface of the bandage in contact with the patient. In such
cases, the rate of release of drug from the adhesive should exceed
the rate of release of drug from the reservoir so that release from
the reservoir by passage through the drug release controlling
microporous material is the rate limiting step for drug
administration by the device of the invention. Of course, when the
adhesive is disposed only about the periphery of the bandage face,
the adhesive need not be permeable to passage of the drug.
Various occlusive and non-occlusive, flexible or non-flexible
backing members can be used in the adhesive bandage of the
invention. Suitable backings include cellophane, cellulose acetate,
ethylcellulose, plasticized vinylacetate-vinylchloride copolymers,
polyethylene terephthalate, nylon, polyethylene, polypropylene,
polyvinylidenechloride, paper, cloth, and aluminum foil.
Preferably, a flexible occlusive backing is employed to conform to
the shape of the body member to which the adhesive tape is applied
and to enhance administration of the agent to the skin.
To prevent passage of the drug away from the exposed surface of the
pressure-sensitive adhesive prior to use, the adhesive surface of
the tape generally is covered with a protective release film or
foil such as waxed paper. Alternatively, the exposed rear surface
of the backing member can be coated with a low-adhesion backsize
and the bandage rolled about itself. To enhance stability of the
active compounds, the therapeutic bandage usually is packaged
between hermetically sealed polyethylene terephthalate films under
an inert atmosphere, such as gaseous nitrogen.
To use the adhesive bandage of the invention, wherein the drug is
topical, it is applied directly to the area of skin to be treated,
to release a therapeutically effective amount of the agent to the
affected area. For administration of systemic drugs the bandage can
be applied to any area of the patient's skin, with the lower back
and buttocks being the areas of choice. In like manner, the bandage
can be applied to the mucosa of the mouth, for example, by
application to the palate or the buccal mucosa, to obtain
absorption of the drug by the oral mucosa. Although obtaining a
liquid tight adhesive seal between the skin and bandage is
important, it becomes critical in the mouth. Without such a seal,
irrigation of the oral mucosa by saliva will transfer the drug to
the gastrointestinal tract, rather than to circulation through the
oral mucosa. In addition, the bandage of the invention can be used
to administer drugs to other mucosa of the body, for example, it
can be applied to the vaginal mucosa, rectal mucosa, etc. By use of
this invention, one ensures that an accurately measured quantity of
the active drug is available to the site of application.
The following examples are merely illustrative to the present
invention and should not be construed as limiting the scope of the
invention in any way, as these examples and other equivalents
thereof will become apparent to those versed in the art in light of
the present disclosure, drawings and accompanying claims.
EXAMPLE 1
Porous, discrete particles of polymerized poly(vinyl chloride) of
about 100 microns in diameter are prepared by mixing 100 grams of
suspension grade poly(vinyl chloride) resin with 50 grams of octyl
diphenyl phosphate and 10 grams of nitroglycerin. These ingredients
are mixed at room temperature into a sticky, wet mass. Next, the
solvent is allowed to escape to form dry, free flowing, discrete
micro-capsules. 10 grams of the resulting microcapsules of
polyvinylchloride/nitroglycerin are mixed with 100 grams of a 22
percent solution in hexane: isopropyl-acetate (70:30) of a
viscoelastic copolymer of isooctyl acrylate and acrylic acid (94:6)
adhesive to uniformly distribute the microcapsules throughout the
adhesive solution. The resulting slurry is coated onto a cellophane
sheet 10 centimeters in width by 100 centimeters in length and the
solvent removed from the coated film.
When a 5 centimeter by 5 centimeter section is cut from the above
sheet and applied to the skin of a human adult, the resulting
bandage is effective to control the continuous administration of a
daily therapeutically effective dosage of nitroglycerin for the
prophylactic treatment of angina pectoris.
EXAMPLE 2
Dry crystalline powdered megesterol acetate (0.3 gram) in 10 ml.
ethanol is mixed with 25 parts by weight of polydimethylsiloxane, 5
parts by weight of silicone oil and 0.25 parts by weight of
stannous octoate catalyst. The ingredients are mixed until a
homogenous mixture is produced. The mixture is then cast into a
mold and allowed to cure to prepare a matrix having a surface area
of 10 square centimeters and 9 mils thick. One face surface of the
matrix is bonded to a sheet of cellophane. On the other face
surface is placed an ethanol impregnated microporous membrane of
the same external surface area as the matrix. The membrane is sold
by Millipore Corporation and designated to the trade as HA, and is
characterized by a porosity of 60 percent, a pore size of 0.45
microns, and a thickness of 4 mils. Dimethyl silicone rubber
adhesive is coated to a thickness of 2 mils on the membrane. The
adhesive face surface of the completed bandage has an area of 10
square centimeters. The bandage is effective to slowly release
megesterol acetate, and when applied to the female skin, is useful
for fertility control.
EXAMPLE 3
10 milligrams of betamethasone in 10 ml. of propylene glycol is
placed on a sheet of dimethyl silicone rubber having a thickness of
10 mils. The sheet is folded to provide a surface area of 10 square
centimeters on each face and the flaps sealed with silicone
adhesive to provide a thin envelope containing the drug. The top
face of the envelope is removed and replaced with a propylene
glycol impregnated microporous membrane sold by Amicon Corporation
under the designation of PM 30. The membrane is secured to the
envelope by means of adhesive to form a tight seal therewith. The
membrane is characterized by having an anisotropic structure, with
a minimum pore size of 70 angstrom units, an overall porosity of 70
percent, and a thickness of 4 units.
Pressure-sensitive adhesive is prepared by mixing together 90 grams
of polyacrylate solution (ethylacetate: hexane/5:1) containing 25
percent non-volatile matter (obtained by the catalytic
polymerization of isomylacrylate and acrylic acid in the ratio of
95:5 in ethylacetate and then diluting with hexane), 5 grams
polyvinylethylether (reduced viscosity= 0.3 .+-. 0.1), 1 gram
castor oil (USP) and 4 grams polyethyleneglycol 400.
One face surface of the envelope is bonded to a sheet of cellophane
while the external membrane surface is coated with adhesive
prepared above to a thickness of 2 millimeters. The adhesive face
surface of the bandage has an area of 100 square centimeters. The
bandage is effective to release a therapeutically effective daily
dosage of the drug when applied to the skin for control of
psoriasis.
EXAMPLE 4
3 grams of a polyacrylonitrile fiber sold under the trade
designation Orlon by E. I. DuPont de Nemours & Co. was
dissolved in 30 grams of an aqueous solution comprising 70 percent
by weight of zinc chloride. After the solution was cooled to about
25.degree.C, 0.250 grams of DIGOXIN was added to the solution.
Thereupon, the solution was added drop-wise through a No. 21
hypodermic needle into an acetone bath whereupon particles were
formed. After being stirred for about thirty minutes in the
acetone, the particles were removed and placed in a water bath for
four hours at room temperature to leach our residual acetone and
salt.
20 grams of polyvinylethylether (reduced visosity= 5.0 .+-.
0.5)
4 grams of polyvinylethylether (reduced viscosity= 0.3 .+-.
0.1)
4 grams of glycerol ester of hydrogenated rosin and
2 grams polyethyleneglycol 400
The resulting DIGOXIN capsules are mixed with pressure-sensitive
adhesive prepared above to uniformly distribute the microcapsules
throughout the adhesive. Immediately thereafter, the adhesive
mixture is coated onto one surface of a 1000 square centimeter
Mylar sheet. A 5 centimeter by 5 centimeter area of the resulting
bandage can be used for control of cardiac disorders.
Thus, this invention provides an easy to use device for
administering systemically active drugs through the skin or oral
mucosa and other body mucosa. Uncertainties of administration
through the gastrointestinal tract are avoided and a controlled
constant level of drug in circulation can be obtained. Treatment is
begun by applying the bandage to the skin or mucosa and terminated
by removing it therefrom. The bandage can contain and administer
the complete dosage requirements for a particular time period, for
example, 24 hours. Intervention by the patient is required only to
apply and remove the bandage, so that uncertainties through patient
error are eliminated.
Moreover, this invention provides a reliable and easy to use device
for administering topically active drugs directly to the affected
areas of skin or mucosa. Uncertainties resulting from topical
application of these agents, from creams and solutions, are not
encountered; and a precisely determined amount of the drug is
applied in a controlled manner.
Although the product of this invention has been referred to as an
adhesive bandage, those skilled in the art will appreciate that the
term "adhesive bandage" as used herein includes any product having
a backing member and a pressure-sensitive adhesive face surface.
Such products can be provided in various sizes and configurations,
including tapes, bandages, sheets, plasters, and the like.
* * * * *